Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Get Free Report) insider Neal Flomenberg sold 232,968 shares of the company's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $1.09, for a total transaction of $253,935.12. Following the completion of the transaction, the insider now owns 3,595,608 shares in the company, valued at approximately $3,919,212.72. This trade represents a 6.08 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Neal Flomenberg also recently made the following trade(s):
- On Monday, March 10th, Neal Flomenberg sold 70,384 shares of Tevogen Bio stock. The shares were sold at an average price of $1.09, for a total transaction of $76,718.56.
- On Thursday, March 6th, Neal Flomenberg sold 88,519 shares of Tevogen Bio stock. The shares were sold at an average price of $1.10, for a total transaction of $97,370.90.
- On Tuesday, March 4th, Neal Flomenberg sold 14,639 shares of Tevogen Bio stock. The shares were sold at an average price of $1.28, for a total transaction of $18,737.92.
Tevogen Bio Stock Up 5.4 %
NASDAQ TVGN opened at $1.17 on Friday. The company has a 50-day moving average of $1.36 and a 200-day moving average of $1.17. Tevogen Bio Holdings Inc. has a 12 month low of $0.26 and a 12 month high of $6.53.
Institutional Trading of Tevogen Bio
Institutional investors and hedge funds have recently bought and sold shares of the business. HGC Investment Management Inc. acquired a new stake in Tevogen Bio during the 3rd quarter worth approximately $82,000. China Universal Asset Management Co. Ltd. acquired a new stake in Tevogen Bio during the 4th quarter worth approximately $38,000. Northern Trust Corp increased its position in Tevogen Bio by 13.0% during the 4th quarter. Northern Trust Corp now owns 118,415 shares of the company's stock worth $122,000 after purchasing an additional 13,595 shares in the last quarter. Barclays PLC increased its position in Tevogen Bio by 39.2% during the 4th quarter. Barclays PLC now owns 45,600 shares of the company's stock worth $48,000 after purchasing an additional 12,847 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in Tevogen Bio by 74.2% during the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company's stock worth $40,000 after purchasing an additional 16,695 shares in the last quarter.
Wall Street Analyst Weigh In
Separately, D. Boral Capital reaffirmed a "buy" rating and set a $10.00 price objective on shares of Tevogen Bio in a research note on Tuesday.
Get Our Latest Report on TVGN
Tevogen Bio Company Profile
(
Get Free Report)
Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
